UPDATE - Teva Pharmaceutical (TEVA) Issues Press Release Regarding Generic Biaxin XL
More News related to ABT
- Abbott (ABT) sues Teva (TEVA) over its drug for kidney patients, Zemplar
- The Deal Names Abbott Top Dealmaker for Second Consecutive Year
- Hilliard Lyons Downgrades Abbott Labs (ABT) to Long-Term Buy
- Abbott to Develop New Heart Failure Test on ARCHITECT(R) Immunochemistry Diagnostics Platform
- Morgan Joseph Initiates Coverage on Boston Scientific (BSX) with a Hold; Shares Fully Valued
More News related to TEVA
- Abbott (ABT) sues Teva (TEVA) over its drug for kidney patients, Zemplar
- Merriman Curhan Ford Initiates Coverage on Antares Pharma (AIS) with a Buy; Cutting Edge Drug Delivery Business
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Teva Receives Final Approval for Generic Prevacid(R) Delayed-Release Capsules
- Teva Pharma (TEVA) Announces Generic Version of Prevacid Does Not Infringe on Patents
More News related to FDA
- Cornerstone Therapeutics (CRTX) Receives Warning Letter From FDA
- Pfizer (PFE) Gets Okay for Bipolar Treatment Geodon from U.S. FDA
- Intuitive Surgical (ISRG) Receives Japanese Approval for da Vinci
- Dendreon Corp. (DNDN) Receives U.S. FDA Complete Response for PROVENGE CRPC Treatment
- Boston Scientific (BSX) Receives 510(k) Clearance and CE Mark on WallFlex
UPDATE - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced that the United States Court of Appeals for the Federal Circuit has vacated a June 2005 ruling by the U.S. District Court for the Northern District of Illinois, which had granted Abbott's (NYSE: ABT) motion for a preliminary injunction related to Teva's generic Biaxin XL Filmtabs.
Teva's Abbreviated New Drug Application (ANDA) for the antibiotic Clarithromycin Extended Release Tablets, 500 mg has already been granted final approval by the U.S. Food and Drug Administration. Annual brand product sales in the U.S. were approximately $255 million for the twelve months ended March 2006, based on IMS data.
Teva is currently involved in patent litigation with Abbott concerning this product. A bench trial has been scheduled for March 2007.
Related Categories
FDAStocks Mentioned
+0.68
-0.32Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
